Microvast reported a 16.4% increase in revenue to $75.0 million, exceeding guidance, and achieved a record backlog of $675.9 million, up 541.9% year-over-year. Gross margin improved from 7.5% to 15.3%. The company is focused on ramping up production in its Huzhou, China facility and commencing trial production in its Clarksville, Tennessee facility in Q4.
Revenue increased 16.4% year-over-year to $75.0 million, exceeding guidance.
Record backlog of $675.9 million, up 541.9% year-over-year.
Gross margin increased to 15.3% from 7.5% in the prior year.
Net loss improved to $26.1 million compared to $44.2 million in the prior year.
The company expects to add to its record backlog, with continued growth in orders and backlog for the rest of the year. For Q3 2023, the Company expects revenue to be in the range of $72 million to $80 million and $348 million to $368 million for the full year 2023. Capital expenditures for the full year are anticipated to be in the range of $180.0 million to $210.0 million